Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Loncastuximab Tesirine et Rituximab suivis de DA-EPOCH-R pour le traitement des patients atteints d'un lymphome diffus à grandes cellules B à haut risque

10 novembre 2026 mis à jour par: University of California, Davis

Une étude de phase 2 sur le loncastuximab tesirine et le rituximab (Lonca-R) suivis de DA-EPOCH-R dans le lymphome diffus à grandes cellules B à haut risque non traité auparavant

This phase II trial evaluates whether loncastuximab tesirine and rituximab followed by dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone works to treat patients with high risk diffuse large B-cell lymphoma. Loncastuximab tesirine is a monoclonal antibody called loncastuximab, linked to a drug called tesirine. It is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD19 receptors, and delivers tesirine to kill them. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Chemotherapy drugs such as doxorubicin, vincristine, and cyclophosphamide work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving loncastuximab tesirine and rituximab in combination with dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone may be more effective at treating high risk diffuse large B-cell lymphoma patients than standard treatments.

Aperçu de l'étude

Description détaillée

PRIMARY OBJECTIVE:

I. To obtain a preliminary estimate of the anti-tumor activity of loncastuximab tesirine and rituximab (lonca-R) in newly diagnosed double-expressor lymphoma (DEL) and double-hit lymphoma (DHL).

SECONDARY OBJECTIVES:

I. To obtain additional efficacy measures of lonca-R in newly diagnosed DEL and DHL.

II. To assess safety and tolerability of lonca-R followed by dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone (DA-EPOCH-R) as coded by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0.

OUTLINE:

Patients receive rituximab intravenously (IV), loncastuximab tesirine IV, etoposide IV, doxorubicin IV, vincristine IV, prednisone orally (PO), and cyclophosphamide IV on study. Patients also undergo collection of blood samples and bone marrow aspiration and biopsy at screening and computed tomography (CT) or positron emission tomography (PET)/CT at screening, throughout the study, and during follow up.

Type d'étude

Interventionnel

Inscription (Estimé)

24

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • California
      • Sacramento, California, États-Unis, 95817
        • University of California Davis Comprehensive Cancer Center
      • San Diego, California, États-Unis, 92037
        • UC San Diego Moores Cancer Center

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Histologically or cytologically confirmed untreated DEL and DHL diffuse large B-cell lymphoma (DLBCL) meeting the World Health Organization (WHO) criteria for DEL - MYC greater than 40% and BCL2 greater than 50% by immunohistochemistry, or high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (double-hit and/or triple-hit are included)

  • Measurable disease by CT or PET/CT scan, with one or more sites of disease >= 1.5 cm in longest dimension

  • Age >= 18 years at time of consent

  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

  • Life expectancy >= 6 months

  • Leukocytes >= 2,500/uL

  • Absolute neutrophil count >= 1,000/uL

  • Platelets >= 100,000/uL

  • Hemoglobin >= 8 g/dL

  • Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level =< 3 x ULN may be enrolled)

  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x ULN (AST and/or ALT =< 5 x ULN for patients with liver involvement)

  • Alkaline phosphatase =< 2.5 x ULN (=< 5 x ULN for patients with documented liver involvement or bone metastases)

  • Creatinine clearance >= 30 mL/min by Cockcroft-Gault

  • Activated partial thromboplastin time (aPTT) =< 1.5 x ULN (This applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation, such as low-molecular-weight heparin or warfarin, should be on a stable dose)

  • Transthoracic echocardiography (TTE) or multigated acquisition scan (MUGA) ejection fraction greater than 40%

  • Women of child-bearing potential (WOCBP) must agree to use a highly effective method of contraception from the time of giving informed consent until at least 10 months after the last dose of study drug. Men with female partners who are of childbearing potential must agree to use a highly effective method of contraception from the time of giving informed consent until at least 7 months after the last dose of study drug

  • Ability to understand and the willingness to sign a written informed consent document

  • Human immunodeficiency virus (HIV) infected patients:

    • No history of acquired immunodeficiency syndrome (AIDS)-defining conditions other than lymphoma or history of CD4+ T-cells below 200/mm^3 prior to beginning combination anti-retroviral therapy (ART)
    • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
    • At time of study entry CD4+ T-cells must have recovered from prior lymphoma therapy to >= 250/mm^3
    • At the time of study entry, the HIV viral load must be undetectable by standard laboratory assay
    • During prior lymphoma therapy, patients must not have experienced documented infections attributed to the HIV positive (+) status
    • No history of non-adherence to ART and willing to adhere to ART while on study
    • Antiretroviral drugs with overlapping or similar toxicity profiles as study agents not allowed

Exclusion Criteria:

  • Current/ prior use of:

    • Lymphoma treatment, except for:

      • 1 cycle of DA-EPOCH-R or rituximab, cyclophosphamide, doxorubicin (Adriamycin) vincristine (Oncovin) and prednisolone (R-CHOP)
      • Radiotherapy > 2 weeks of initiating study treatment
      • Nitrosoureas or mitomycin C > 6 weeks of initiating study treatment
      • Steroid treatment for DLBCL or steroid monotherapy to stabilize disease while awaiting fluorescence in situ hybridization (FISH)
      • Other cancer therapies (e.g., prostate, breast hormonal-based therapy) per the principal investigator's discretion
    • Anthracycline greater than 50 mg/m^2 (total lifetime) for a prior malignancy

    • Complementary and alternative medications (CAM) within 1 week prior to initiating study treatment

    • Treatment with any other investigational agent for any indication within 3 weeks prior to initiating study treatment

    • Loncastuximab tesirine or rituximab with progression within 6 months of initiating study treatment

    • Oral or intravenous (IV) antibiotics within 2 weeks prior to initiating study treatment. Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible

    • Live, attenuated influenza vaccine within 4 weeks prior to initiating study treatment

  • Immunosuppressive medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor, such as anti-tumor necrosis factor [TNF] agents) within 14 days prior to initiating study treatment. The following are exceptions to this criterion:

    • Steroids
    • Bisphosphonate therapy for symptomatic hypercalcemia or for other reasons (e.g., bone metastasis or osteoporosis)
  • Known uncontrolled central nervous system (CNS) involvement by lymphoma, including leptomeningeal involvement

  • History of hypersensitivity to anti-CD19 antibodies, loncastuximab tesirine, or any agents used in DA-EPOCH-R

  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in study

  • Clinically significant third space fluid accumulation (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath)

  • Breastfeeding or pregnancy

  • Clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; or inherited liver disease

    • Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HbsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible
    • Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA)
  • Documented eczema, psoriasis, or lichen simplex chronicus of vitiligo with dermatologic manifestations (e.g., patients with psoriatic arthritis would be excluded), unless the following apply:

    • Affected skin covers less than 10% of body surface area (BSA)
    • Disease is well controlled at baseline and only requires low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%)
    • No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
  • Known active tuberculosis (TB)

  • Severe infections within 4 weeks prior to initiating study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia

  • Major surgical procedure within 28 days prior to initiating study treatment or anticipation of need for a major surgical procedure during the course of the study

  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Treatment (Lonca-R, DA-EPOCH-R)

Patients receive rituximab IV, loncastuximab tesirine IV, etoposide IV, doxorubicin IV, vincristine IV, prednisone PO, and cyclophosphamide IV on study. Patients also undergo collection of blood samples and bone marrow aspiration and biopsy at screening and CT or PET/CT at screening, throughout the study, and during follow up.

Given IV

Autres noms:
  • Cytoxane
  • CTX
  • (-)-Cyclophosphamide
  • 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroéthyl)amino]tétrahydro-, 2-oxyde, monohydraté
  • Carloxane
  • Ciclofosfamida
  • Ciclofosfamide
  • Cicloxal
  • Clafène
  • Clapène
  • CP monohydraté
  • CYCLO-cellule
  • Cycloblastine
  • Cyclophosphame
  • Cyclophosphamide monohydraté
  • Monohydrate de cyclophosphamide
  • Cyclophosphamide
  • Cyclophosphane
  • Cyclostine
  • Cytophosphane
  • Fosfaséron
  • Genoxal
  • Genuxal
  • Lédoxine
  • Mitoxane
  • Néosar
  • Revimmuniser
  • Syklofosfamide
  • WR-138719

Given PO

Autres noms:
  • Deltasone
  • Orasone
  • .delta.1-Cortisone
  • 1, 2-Déhydrocortisone
  • Adasone
  • Cortancyl
  • Dacortine
  • DeCortin
  • Décortisyl
  • Décorton
  • Delta 1-Cortisone
  • Delta-Dôme
  • Deltacortène
  • Deltacortisone
  • Deltadéhydrocortisone
  • Deltison
  • Delta
  • Éconosone
  • Lisacort
  • Méprosona-F
  • Métacortandracine
  • Méticorten
  • Ofisolone
  • Panafort
  • Panasol-S
  • Paracort
  • Perrigo Prednisone
  • PRED
  • Prédicteur
  • Prédiction
  • Prednicen-M
  • Prednicort
  • Prednidib
  • Prednilonga
  • Prédilection
  • Intensol de prednisone
  • Prednison
  • Prednitone
  • Promifène
  • Rayos
  • Servison
  • SK-Prednisone

Given IV

Autres noms:
  • Adriablastine
  • Hydroxydaunomycine
  • Hydroxyl Daunorubicine
  • Hydroxyldaunorubicine

Given IV

Autres noms:
  • Rituxan
  • MabThera
  • ABP 798
  • BI 695500
  • Anticorps monoclonal C2B8
  • Anticorps Chimère Anti-CD20
  • CT-P10
  • IDEC-102
  • IDEC-C2B8
  • Anticorps monoclonal IDEC-C2B8
  • PF-05280586
  • Riabni
  • Rituximab ABBS
  • Rituximab ARRX
  • Rituximab biosimilaire ABP 798
  • Rituximab biosimilaire BI 695500
  • Biosimilaire Rituximab CT-P10
  • Rituximab biosimilaire GB241
  • Rituximab biosimilaire IBI301
  • Rituximab biosimilaire JHL1101
  • Rituximab biosimilaire PF-05280586
  • Rituximab biosimilaire RTXM83
  • Rituximab biosimilaire SAIT101
  • Rituximab biosimilaire SIBP-02
  • rituximab biosimilaire TQB2303
  • Rituximab PVVR
  • rituximab-abbs
  • Rituximab-arrx
  • Rituximab-pvvr
  • RTXM83
  • Ruxience
  • Truxima

Given IV

Autres noms:
  • Magnétoscope
  • Leurocristine
  • Vincristine

Given IV

Autres noms:
  • Déméthyl épipodophyllotoxine éthylidine glucoside
  • EPEG
  • Dernière configuration
  • Toposar
  • Vepesid
  • PV 16
  • VP16-213
  • VP-16
  • VP-16-213
  • VP16

Given IV

Autres noms:
  • Zynlonta
  • ADCT-402
  • ADC ADCT-402
  • Anti-CD19 PBD-conjugué ADCT-402
  • Loncastuximab Tesirine-lpyl

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Complete response rate
Délai: First dose through cycle 2 (1 cycle = 3 weeks)

Evaluated per 2014 Lugano criteria. An exact 95% confidence interval will be calculated.

First dose through cycle 2 (1 cycle = 3 weeks)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Overall survival rate
Délai: First dose to off study, assessed up to 3 years

Will be estimated using the product-limit of Kaplan and Meier.

First dose to off study, assessed up to 3 years
Relapse/progression free survival
Délai: First dose (cycle 1 day 6 rituximab dose) until relapse/progression or off study, whichever occurs first, assessed up to 3 years

Will be estimated using the product-limit of Kaplan and Meier.

First dose (cycle 1 day 6 rituximab dose) until relapse/progression or off study, whichever occurs first, assessed up to 3 years
Overall response rate (complete response + partial response)
Délai: First dose through cycle 2 (1 cycle = 3 weeks)

Defined as the proportion of participants who have partial or complete response from the start of study treatment through completion of 2 cycles. Evaluated per 2014 Lugano criteria. An exact 95% confidence interval will be calculated.

First dose through cycle 2 (1 cycle = 3 weeks)
Incidence of adverse events
Délai: First dose through 30 days post last dose

Will evaluate the number of participants experiencing treatment-related adverse events, classified by severity and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Observed toxicities will be summarized by type (organ affected or laboratory determination), severity, date of onset, duration, and attribution.

First dose through 30 days post last dose

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Joseph M Tuscano, University of California, Davis

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

24 mai 2023

Achèvement primaire (Estimé)

1 mai 2027

Achèvement de l'étude (Estimé)

15 décembre 2027

Dates d'inscription aux études

Première soumission

10 octobre 2022

Première soumission répondant aux critères de contrôle qualité

27 octobre 2022

Première publication (Réel)

31 octobre 2022

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

16 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

10 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner